MATERIAL CHANGE REPORT

PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102

1. **Name and Address of Company:**

   Miraculins Inc. (the "Corporation")
   6 – 1250 Waverley Street
   Winnipeg, Manitoba R3T 6C6

2. **Date of Material Change:**

   September 21, 2010

3. **News Release:**

   The Corporation issued a press release regarding the material change on September 21, 2010, a copy of which is attached hereto.

4. **Summary of Material Change:**

   Miraculins Announces Exercise of Warrants for Proceeds of $850,000

5. **Full Description Of Material Change:**

   See attached Schedule "A".

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:**

   Not Applicable.

7. **Omitted Information:**

   Not Applicable.

8. **Executive Officer:**

   Eric R. Johnstone, Chief Financial Officer
   Tel: (204) 453-1408

DATED at Winnipeg, Manitoba this 23th day of September, 2010.

MIRACULINS INC.

Per: *"Eric Johnstone"*
Eric R. Johnstone, CFO

SCHEDULE "A"

Miraculins Announces Exercise of Warrants for Proceeds of $850,000

WINNIPEG, Manitoba – September 21, 2010 - Miraculins Inc. (TSX-V:MOM) (the "Company"), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces that it has received proceeds of $850,000 from the exercise of 8,500,000 warrants issued pursuant to a private placement offering that closed on April 1, 2010 (the "Offering"). The expiry date was accelerated to September 20, 2010 based upon notice provided to all warrant holders of record on August 17, 2010 (the "Notice"). The Company will issue 8,500,000 common shares in exchange for the exercised warrants, representing 83% of the total warrants issued pursuant to the Offering.

"We are pleased by the confidence and support shown by our shareholders through the exercise of a significant number of these warrants," stated Christopher J. Moreau, president and chief executive officer of Miraculins Inc.

As outlined in the Notice, all remaining unexercised warrants from the Offering have now expired.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on non-invasive tests for unmet clinical needs. Miraculins is bridging the gap between commercially available diagnostic tests and research conducted at leading research institutions around the world. Miraculins recently acquired the PREVU* Skin Cholesterol Test, an FDA cleared product for cardiovascular risk assessment. Additionally, the Company's preeclampsia program, a suite of biomarkers for the devastating disease of pregnancy called preeclampsia, is partnered with Alere, Inc. (NYSE:ALR) (formerly known as Inverness Medical Innovations), one of the world's largest diagnostic companies. For further information please visit Miraculins website at www.miraculins.com.

For more information, please contact:

Christopher J. Moreau
President and CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1546
info@miraculins.com
www.miraculins.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for *products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.*

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

** - trademark*